Study published in Clinical Breast Cancer supports MammaTyper® LRP as a quantitative molecular tool for risk assessment and chemotherapy decision-making.

Berlin, Germany — September 11, 2026

A new study published in Clinical Breast Cancer provides clinical evidence supporting the prognostic value of the MammaTyper® LRP score in patients with early-stage luminal breast cancer. The study, led by Professor Ling Xu of Peking University First Hospital, demonstrates that LRP is an independent prognostic factor and may help identify patients with a low risk of distant recurrence who may have limited benefit from adjuvant chemotherapy.

“MammaTyper® has the potential to become a broadly accessible multigene expression profiling tool offering guidance on precision breast cancer treatment.”
— Professor Ling Xu, Peking University First Hospital

Background & Unmet Need

Luminal breast cancer, generally characterized by estrogen receptor (ER) and/or progesterone receptor (PR) positivity and HER2 negativity, accounts for a substantial proportion of breast cancer cases. Although endocrine therapy is a cornerstone of treatment, determining whether adjuvant chemotherapy is necessary can be challenging. Multigene expression assays can provide additional biological information beyond conventional clinicopathological factors and support more individualized treatment decisions.

Oncotype DX®, the established 21-gene assay, has been widely used internationally to support treatment decisions in early-stage hormone receptor-positive, HER2-negative breast cancer. However, access to the test remains limited in many parts of the world. MammaTyper® has previously demonstrated in direct comparative studies the ability to identify low-risk patients with Oncotype DX® Recurrence Score ≤25. The newly published study provides additional evidence of the prognostic relevance of the MammaTyper® LRP score.

Key Study Findings

The retrospective study included 402 patients with early-stage luminal breast cancer treated at Peking University First Hospital between 2014 and 2018. Patients had T1–2, N0–1 disease, and the median follow-up exceeded seven years. The study reported:

• LRP score was an independent prognostic factor, with an adjusted hazard ratio (HR) of 0.37 in multivariable analysis.
• Patients in the LRP low-risk group achieved a 9-year distant disease-free survival (DDFS) rate of 96.2%, compared with 87.0% in the LRP high-risk group.
• The difference between the two groups was statistically significant (HR=0.28; p=0.0021).
• Among patients classified as LRP low risk, 9-year DDFS was favorable and broadly comparable regardless of whether they received adjuvant chemotherapy, suggesting LRP may help identify patients with a favorable long-term prognosis.

“Assessing the prognosis of early luminal breast cancer solely on the basis of conventional clinicopathological characteristics has limitations and may contribute to overtreatment in some patients. Oncotype DX® and other genomic assays generally are costly and have limited accessibilities in many parts of the world. MammaTyper® has previously demonstrated the ability to identify low-risk population characterized by Oncotype DX® (RS≤25), and our study further validates its prognostic value. With its lower testing cost and local availability, MammaTyper® has the potential to become a broadly accessible multigene expression profiling tool offering guidance on precision breast cancer treatment.”
— Professor Ling Xu, Principal Investigator, Peking University First Hospital

Reference

Ding M, et al. Clinical validation of the MammaTyper® LRP model for identification of low risk patients with early-stage ER+/HER2- breast cancer: from subtyping to chemotherapy de-escalation. Clinical Breast Cancer. Available online 24 August 2026.